Amgen Inc. Stock News

Amgen (AMGN) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings its

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.

Amgen (AMGN) came out with quarterly earnings of $4.96 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings of $4.70 per share a year ago.

In contrast to market expectations, shares of Amgen, Inc. (NASDAQ:AMGN) remained flat even as the biotechnology giant exceeded third-quarter earnings estimates and once again raised its financial gui

The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.

Amgen Inc.'s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. The company posted net income

Amgen , which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.

Dividend stocks haven't been top performers in 2023. Over lengthy holding periods, though, high-quality dividend stocks tend to deliver above-average returns.

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

In the latest trading session, Amgen (AMGN) closed at $276.12, marking a +1.12% move from the previous day.

When massive acquisitions take place, job cuts typically follow. Such is the case with Amgen (NASDAQ: AMGN ) today.

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Amgen (AMGN). But which of these two stocks is more attractive to valu